BMG Pharma Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
25
- Latest Deal Type
-
Angel
- Investors
-
3
BMG Pharma General Information
Description
Developer of medical devices and functional ingredients designed for oral cavity care, osteoarthritis, and aesthetic dermatology. The company deals with the creation of new medical devices and their subsequent marketing to address specific needs by out-licensing its products to a global network of partners to meet direct patient needs with innovative self-prescription solutions, enabling the medical community to optimize associated treatment outcomes.
Contact Information
Website
www.bmgpharma.comCorporate Office
- Via De Castillia, 23
- 20124 Milan
- Italy
Corporate Office
- Via De Castillia, 23
- 20124 Milan
- Italy
BMG Pharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Angel (individual) | 07-Nov-2022 | Completed | Generating Revenue | |||
| 1. Early Stage VC | 29-Apr-2021 | Completed | Generating Revenue |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
BMG Pharma Patents
BMG Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4249078-A1 | Sulphite-free oral hygiene formulations designed to counteract tooth pigmentation | Pending | 23-Mar-2022 | ||
| JP-2023503887-A | Cross-linked hyaluronic acid butyrate or butyrate-formate derivatives and method for cross-linking thereof | Active | 20-Nov-2019 | ||
| CA-3158866-A1 | Crosslinked butyrate or butyrate-formate derivatives of hyaluronic acid and the crosslinking process thereof | Pending | 20-Nov-2019 | ||
| WO-2021099977-A1 | Crosslinked butyrate or butyrate-formate derivatives of hyaluronic acid and the crosslinking process thereof | Inactive | 20-Nov-2019 | ||
| JP-7747335-B2 | Crosslinked hyaluronic acid butyrate or butyrate-formate derivatives and method for crosslinking same | Active | 20-Nov-2019 | C08B37/0072 |
BMG Pharma Signals
BMG Pharma Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Angel (individual) | Minority | |||
| Friulia Finanziaria FVG | PE/Buyout | Minority | ||
| Medeor Associates | Growth/Expansion | Minority |
BMG Pharma Investments & Acquisitions (2)
BMG Pharma’s most recent deal was a Joint Venture with BMG Aesthetic. The deal was made on 02-Apr-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| BMG Aesthetic | 02-Apr-2025 | Joint Venture | Clinics/Outpatient Services | ||
| Sigea (Trieste) | 01-Jun-2018 | Merger/Acquisition | Office Services (B2B) |
BMG Pharma Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Bmg Biochemical | Torviscosa, Italy | 2025 |
BMG Pharma FAQs
-
When was BMG Pharma founded?
BMG Pharma was founded in 2018.
-
Where is BMG Pharma headquartered?
BMG Pharma is headquartered in Milan, Italy.
-
What is the size of BMG Pharma?
BMG Pharma has 25 total employees.
-
What industry is BMG Pharma in?
BMG Pharma’s primary industry is Pharmaceuticals.
-
Is BMG Pharma a private or public company?
BMG Pharma is a Private company.
-
What is BMG Pharma’s current revenue?
The current revenue for BMG Pharma is .
-
How much funding has BMG Pharma raised over time?
BMG Pharma has raised $2.39M.
-
Who are BMG Pharma’s investors?
, Friulia Finanziaria FVG, and Medeor Associates have invested in BMG Pharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process